- Previous Rank17
- Revenue 3 Yr Annual Growth Rate32%
- Revenue 3 Yr Growth Rank48
- EPS 3 Yr Annual Growth Rate58%
- EPS 3 Yr Growth Rank30
- Total Return 3 Yr Annual Rate-4%
- Total Return 3 Yr Rank96
Hepatitis C treatments are an integral part of the biotech’s product line. Recent approval for a competitor’s comprehensive Hep C drug adds new pressure.
Looking for leads, investment insights, or competitive intelligence?Buy Now
Company Information
| Location | Foster City, Calif. |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Current Streak | 3 |
| Years on List | 8 |
| CEO | John Milligan |
| Website | http://www.gilead.com |
Revenue and net income for the four quarters ended on or before April 30, 2017. Total return for the period ended June 30, 2017.
Revenue, Net Income
| Revenue past four quarters ($M) | $29,101 |
| Net Income past four quarters ($M) | $12,637 |
Growth Rates and Ranks
| Revenue 3 Yr Growth Rank | 48 |
| Revenue 3 Yr Annual Growth Rate | 32% |
| EPS 3 Yr Growth Rank | 30 |
| EPS 3 Yr Annual Growth Rate | 58% |
| Total Return 3 Yr Rank | 96 |
| Total Return 3 Yr Annual Rate | -4% |
| Beat S&P 500 (9.6%) | no |
| P/E Ratio | 9 |
